Decisive point for gensight in the short termSolid'action which is about to exceed probably € 10 in the short term if we go above € 9.35 at 11:45 am.
Gensight Biologics SA
No trades
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.1299 EUR
−14.00 M EUR
1.50 M EUR
154.10 M
About Gensight Biologics SA
Sector
Industry
CEO
Laurence Rodriguez
Website
Headquarters
Paris
Founded
2012
IPO date
Jul 13, 2016
IPO offer price
8.86 USD
Identifiers
2
ISINFR0013183985
GenSight Biologics SA is a clinical-stage gene therapy company, which engages in research and development of novel therapies for mitochondrial and neurodegenerative diseases of the eye. It also focuses on central nervous system diseases. The company was founded by Bernard Jacques Alex Gilly, Botond Roska, Jean Bennett, Connie Cepko, Luk H. Vandenberghe, Serge Picaud and Jose-Alain Sahel in 2012 and is headquartered in Paris, France.
Related stocks
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of SIGHT is 0.0897 EUR — it hasn't changed in the past 24 hours. Watch Gensight Biologics SA stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on EURONEXT exchange Gensight Biologics SA stocks are traded under the ticker SIGHT.
SIGHT stock has fallen by −8.73% compared to the previous week, the month change is a −11.71% fall, over the last year Gensight Biologics SA has showed a −70.10% decrease.
We've gathered analysts' opinions on Gensight Biologics SA future price: according to them, SIGHT price has a max estimate of 0.46 EUR and a min estimate of 0.40 EUR. Watch SIGHT chart and read a more detailed Gensight Biologics SA stock forecast: see what analysts think of Gensight Biologics SA and suggest that you do with its stocks.
SIGHT reached its all-time high on Sep 2, 2016 with the price of 10.8200 EUR, and its all-time low was 0.0904 EUR and was reached on Dec 12, 2025. View more price dynamics on SIGHT chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
SIGHT stock is 6.98% volatile and has beta coefficient of 0.63. Track Gensight Biologics SA stock price on the chart and check out the list of the most volatile stocks — is Gensight Biologics SA there?
Today Gensight Biologics SA has the market capitalization of 17.49 M, it has decreased by −7.07% over the last week.
Yes, you can track Gensight Biologics SA financials in yearly and quarterly reports right on TradingView.
Gensight Biologics SA is going to release the next earnings report on Mar 20, 2026. Keep track of upcoming events with our Earnings Calendar.
SIGHT net income for the last half-year is −6.97 M EUR, while the previous report showed −8.15 M EUR of net income which accounts for 14.55% change. Track more Gensight Biologics SA financial stats to get the full picture.
No, SIGHT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 18, 2025, the company has 12 employees. See our rating of the largest employees — is Gensight Biologics SA on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Gensight Biologics SA EBITDA is −15.39 M EUR, and current EBITDA margin is −1.05 K%. See more stats in Gensight Biologics SA financial statements.
Like other stocks, SIGHT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Gensight Biologics SA stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Gensight Biologics SA technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Gensight Biologics SA stock shows the sell signal. See more of Gensight Biologics SA technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.